In fact, prior to the development of BH3 mimetics with high specificity, ‘pan-BH3 mimetics’ with broad engagement of multiple anti-apoptotic BCL-2 proteins were evaluated in pre-clinical studies, with promising results, including in prostate cancer [188,214,215]. Here, BCL2 is linked to prostate cancer.